Skip to main content

Processa Pharmaceuticals, Inc.

PCSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001533743

No open-market purchases or sales by Processa Pharmaceuticals, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Processa Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of PCSA: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders1314+1
Shares372.6K1.78M+1.41M (+377.9%)
Value$75.9K$341.9K+$266.0K (+350.4%)

New holders (7)

Institutions that held Processa Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to PCSA in Q3 2025
InstitutionSharesValue% of portfolio
Stonepine Capital Management, LLC1,030,200$197.7K0.16%
Two Sigma Securities, LLC36,248$6.96K0.00%
Citigroup Inc34,051$6.53K0.00%
StoneX Group Inc.18,951$3.64K0.00%
Sassicaia Capital Advisers LLC15,977$3.07K0.00%
Miracle Mile Advisors, LLC10,000$1.92K0.00%
Jones Financial Companies LLLP188$400.00%

Sold out (6)

Institutions that held Processa Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of PCSA in Q3 2025
InstitutionShares, Q2 2025Value, Q2 2025
UBS Group AG64,612$13.2K
Alpine Global Management, LLC53,416$10.9K
Cubist Systematic Strategies, LLC41,848$8.58K
Jane Street Group, LLC19,270$3.95K
Sequoia Financial Advisors, LLC11,000$2.25K
SBI Securities Co., Ltd.12$2